Lumen Bioscience: Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection
- FDA clearance of investigational new drug (IND) application - Initiation of multisite Phase 2 study in spring 2022 - Phase 1 pharmacokinetic study completed ...
Read full article »
Lumen is a Washington-based biotechnology company that researches and develops biologic drugs for the treatment of cardiometabolic and inflammatory diseases.
Read more